TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01503905
Drug: Herceptin （post-operative)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
Study: NCT04044729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02276482
Drug: Antibiotic comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
Study: NCT00347555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
Study: NCT00536978
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg IV Daily Over 30 Minutes for 3 Days
Study: NCT00536978
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
Study: NCT00536978
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 IV on Days +1, +3, and +6.
Study: NCT02403193
Drug: PBF-509_320 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBF-509: 320 mg, PO, twice daily (BID)
Study: NCT02403193
Drug: PBF-509_640 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBF-509: 640 mg, PO, twice daily (BID)
Study: NCT02403193
Drug: Combo PBF-509 (160 mg) + PDR001
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Study: NCT02403193
Drug: Combo PBF-509 (320 mg) + PDR001
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Study: NCT02403193
Drug: Combo PBF-509 (640 mg) + PDR001
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Study: NCT02403193
Drug: RP2D (PBF-509+PDR001)_immuno naïve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
Study: NCT02403193
Drug: Experimental: RP2D (PBF-509+PDR001)_immuno treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
Study: NCT02638805
Drug: ITCA 650 Osmotic Mini Pump 20/60 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
Study: NCT02638805
Drug: ITCA 650 Osmotic Mini Pump 60 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
Study: NCT03699631
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
Study: NCT02267382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01165281
Drug: R331333 (referred to as JNS024 ER or CG5503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 25 mg to 200 mg capsule twice daily for 4 weeks.
Study: NCT02863991
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg or 625 mg ONC201
Study: NCT00558285
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
Study: NCT00337766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02730819
Drug: Illuminate Cream
Normalized name: bismuth aluminate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical compound applied daily
Study: NCT01674036
Drug: Genz-682452
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration.
Study: NCT01674036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Genz-682452
Study: NCT03483636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated oral tablet
Study: NCT00901290
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: mg, oral dose
Study: NCT03143218
Drug: SMC placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
Study: NCT02099006
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be applied topically at a 10% concentration
Study: NCT02099006
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounding base to be used alone as a placebo
Study: NCT03103555
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
Study: NCT00808249
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets taken twice a day for 28 days
Study: NCT00808249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets taken twice a day for 28 days
Study: NCT01887249
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04413890
Drug: Dinoprostone vaginal gel
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin gel 0.5, 1 or 2 mg
Study: NCT02537379
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF 400 mg tablets administered orally once daily
Study: NCT02087384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of 0.9% saline
Study: NCT03179514
Drug: Anti-Platelet Drugs
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including aspirin and clopidogrel, etc.
Study: NCT03179514
Drug: Lipid Regulating Drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including statins
Study: NCT03179514
Drug: Coronary Vasodilator
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including nitrates
Study: NCT03179514
Drug: Gualou Xiebai Banxia Decoction & Danshen Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
Study: NCT02045212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection twice a week during 13/26 weeks
Study: NCT02128763
Drug: Omega-3 supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg EPA and 1000 mg DHA per day
Study: NCT02128763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
Study: NCT02357849
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arm description
Study: NCT01758666
Drug: Methotrexate,Calcium folinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00504335
Drug: BIO 300 Capsules
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03641209
Drug: Paracetamol 10mg/mL infusion solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol solution for infusion
Study: NCT01586156
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken twice daily for 6 months
Study: NCT00547378
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
Study: NCT00815906
Drug: SBI-087
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, Single dose
Study: NCT00815906
Drug: SBI-087
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC, Single dose
Study: NCT03148431
Drug: LY3002815
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03148431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01360944
Drug: reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, 100 microgram
Study: NCT02591654
Drug: FLT PET
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
Study: NCT04198662
Drug: Intercostal nerve block ropivacaine with epinephrine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
Study: NCT04198662
Drug: Placebo intercostal nerve block with normal saline
Normalized name: ACS22Q55 NERVE BLOCK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
Study: NCT03701750
Drug: Low Molecular Weight Heparin (enoxaparin sodium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
Study: NCT00016133
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00016133
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02081300
Drug: Oral testosterone undecanoate, LPCN 1021
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02081300
Drug: Topical testosterone gel 1.62 %
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04419493
Drug: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Study: NCT00587873
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
Study: NCT00587873
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
Study: NCT02896907
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02896907
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00970502
Drug: erlotinib + celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
Study: NCT04486963
Drug: Sanhuangjingshimingwan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
Study: NCT00625521
Drug: Cream vehicle for ASF 1096 cream applied twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01760993
Drug: SPD489
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
Study: NCT03056495
Drug: N-hydroxy-N'-phenyl-octanediamide (Vorinostat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
Study: NCT03754062
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Placebo by pill.
Study: NCT00731263
Drug: AZD8055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
Study: NCT00180141
Drug: Elidel-Creme
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02233400
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
Study: NCT01833767
Drug: Cyclophosphamide and Interleukin 2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytoxan IV day 1, IL2 IV days 1-5
Study: NCT03656120
Drug: 0.2mg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
Study: NCT03656120
Drug: 0.5mg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
Study: NCT03656120
Drug: placebo control group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants only take placebos for 12 weeks during the research.
Study: NCT02012608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects undergoing breast conserving therapy
Study: NCT01374776
Drug: intravenous iron carboxymaltose
Normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
Study: NCT03071705
Drug: TKI
Normalized name: Catkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard dose
Study: NCT01994226
Drug: Naproxen 750 mg/250 mg
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days
Study: NCT00703833
Drug: MK0777
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
Study: NCT00999479
Drug: Norethindrone acetate and ethinyl estradiol tablets, USP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc.
Study: NCT01725646
Drug: Omacor®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in 4 g and 2 g Omacor® will take this drug
Study: NCT01725646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in placebo group will take this drug
Study: NCT01774344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching in appearance
Study: NCT00570752
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04251689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline 100 ml
Study: NCT02040818
Drug: tigecycline, N-acetylcysteine, heparin combination
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02345057
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02345057
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01243450
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of acne
Study: NCT01243450
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment of acne
Study: NCT00005776
Drug: Inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric oxide at a concentration of 20 ppm
Study: NCT00005776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% Oxygen
Study: NCT00592995
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 to 30 grams daily
Study: NCT00592995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 to 30 grams daily
Study: NCT00654784
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04034641
Drug: Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
Study: NCT04034641
Drug: Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
Study: NCT01373086
Drug: LFF269
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01373086
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01373086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01741753
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, every morning
Study: NCT02175771
Drug: FS MDPI
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening.
Study: NCT02504268
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003658
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03379012
Drug: Testosterone undecanoate and sunitinib or pazopanib
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
Study: NCT00893048
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00779324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo tablet every morning and 12 Noon
Study: NCT02828111
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01415791
Drug: ICI176,334-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive single dose of ICI176,334-1
Study: NCT01168817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 3 tablets once daily for 4 weeks (Placebo)
Study: NCT00407537
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
Study: NCT01891123
Drug: PTX 175mg/m2, DOC 75mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
Study: NCT01613248
Drug: MK-1602
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.